Ben Tre Pharmaceutical Joint Stock Company (Bepharco, stock code DBT - HOSE) increased its subsidiary ownership.

On June 29, Bepharco completed increasing its ownership in Yen Bai Pharmaceutical JSC to 85.9% of charter capital.

In the financial report for the first quarter of 2021, Bepharco recorded that it owns 82.15% of the charter capital at Yen Bai Pharmaceutical JSC, a unit operating in the field of pharmaceutical production and trading.

Previously, in the first quarter of 2021, DBT recorded sales and service provision of 155.71 billion dong, down 23.76% over the same period last year; profit after tax was negative more than 328 million dong, while the same period profit was 5.97 billion dong.

As such, revenue has dropped sharply compared to last year.

In addition to a significant drop in revenue, in the first quarter of 2021, DBT's financial expenses and selling expenses both increased. In addition, during the period, the Company also recorded more than 1 billion dong of deferred corporate income tax expense while the same period did not arise. Therefore, the profit in the first quarter of 2021 decreased sharply compared to the first quarter of 2020.

In 2021, Ben Tre Pharmaceutical sets a target of consolidated revenue of VND 918.2 billion, profit before and after tax of VND 23.5 billion and VND 19.4 billion, respectively. Expected dividend rate of 20%, paid in cash or shares, of which at least 7% in cash.

Closing the session on June 29, DBT stock closed at the reference price of 14,500 dong/share.